Amundi Has $517.92 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Amundi lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 63.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,133,226 shares of the pharmaceutical company’s stock after selling 1,965,643 shares during the period. Amundi owned about 0.44% of Vertex Pharmaceuticals worth $517,918,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in VRTX. Activest Wealth Management bought a new stake in shares of Vertex Pharmaceuticals during the 1st quarter valued at approximately $25,000. Clal Insurance Enterprises Holdings Ltd grew its stake in shares of Vertex Pharmaceuticals by 450.0% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 45 shares during the last quarter. Access Investment Management LLC acquired a new position in shares of Vertex Pharmaceuticals during the second quarter worth $27,000. Legacy Investment Solutions LLC acquired a new position in shares of Vertex Pharmaceuticals during the second quarter worth $29,000. Finally, Flaharty Asset Management LLC bought a new position in shares of Vertex Pharmaceuticals in the 1st quarter valued at $32,000. Institutional investors own 90.96% of the company’s stock.

Insider Activity at Vertex Pharmaceuticals

In other news, Chairman Jeffrey M. Leiden sold 53,604 shares of Vertex Pharmaceuticals stock in a transaction on Friday, November 14th. The shares were sold at an average price of $440.72, for a total value of $23,624,354.88. Following the completion of the sale, the chairman owned 24,026 shares in the company, valued at $10,588,738.72. The trade was a 69.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Trading Down 1.2%

Shares of Vertex Pharmaceuticals stock opened at $457.36 on Friday. The business has a 50-day moving average price of $420.74 and a two-hundred day moving average price of $425.42. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.68. The company has a market cap of $116.04 billion, a P/E ratio of 32.25 and a beta of 0.32.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.58 by $0.22. Vertex Pharmaceuticals had a return on equity of 23.51% and a net margin of 31.35%.The company had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same period in the previous year, the business earned $4.38 EPS. The firm’s revenue was up 11.0% compared to the same quarter last year. Equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on VRTX. Leerink Partnrs raised Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 25th. JPMorgan Chase & Co. upped their price objective on Vertex Pharmaceuticals from $517.00 to $530.00 and gave the company an “overweight” rating in a research note on Wednesday, October 8th. UBS Group dropped their price objective on shares of Vertex Pharmaceuticals from $553.00 to $546.00 and set a “buy” rating for the company in a report on Friday, November 7th. Evercore ISI reduced their target price on shares of Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating on the stock in a report on Thursday, September 11th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $495.85.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.